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Abstract
Aims/hypothesis Intronic single nucleotide polymorphisms
(SNPs) in the CDKAL1 gene are associated with risk of de-
veloping type 2 diabetes. A strong correlation between risk
alleles and lower levels of the non-coding RNA,CDKAL1-v1,
has recently been reported in whole blood extracted from
Japanese individuals. We sought to replicate this association
in two independent cohorts: one using whole blood from
white UK-resident individuals, and one using a collection of
human pancreatic islets, a more relevant tissue type to study
with respect to the aetiology of diabetes.
Methods Levels of CDKAL1-v1 were measured by real-time
PCR using RNA extracted from human whole blood (n=70)
and human pancreatic islets (n=48). Expression with respect
to genotype was then determined.
Results In a simple linear regression model, expression of
CDKAL1-v1 was associated with the lead type 2 diabetes-
associated SNP, rs7756992, in whole blood and islets. How-
ever, these associations were abolished or substantially re-
duced in multiple regression models taking into account
rs9366357 genotype: a moderately linked SNP explaining a
much larger amount of the variation inCDKAL1-v1 levels, but
not strongly associated with risk of type 2 diabetes.
Conclusions/interpretation Contrary to previous findings, we
provide evidence against a role for dysregulated expression of
CDKAL1-v1 in mediating the association between intronic
SNPs in CDKAL1 and susceptibility to type 2 diabetes. The
results of this study illustrate how caution should be exercised
when inferring causality from an association between disease-
risk genotype and non-coding RNA expression.
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eQTL Expression quantitative trait loci
GWAS Genome-wide association studies
LD Linkage disequilibrium
ms2 2-Methylthio
SNP Single nucleotide polymorphism
SR Serine/arginine-rich
Introduction
One of the most robust associations between common genetic
variation and type 2 diabetes risk, reported in European and
Asian populations, involves intronic single nucleotide poly-
morphisms (SNPs) in the CDKAL1 gene, encoding CDK5
regulatory subunit associated protein 1-like 1 [1]. CDKAL1
encodes a methylthiotransferase that catalyses the 2-
methylthio (ms2) modification of various substrates, including
the ms2 addition to N6-threonyl-carbamoyladenosine at posi-
tion 37 of tRNALys(UUU) [2]. The ms2 modification of
tRNALys(UUU) stabilises the interaction with its cognate co-
dons, allowing for efficient translation [3]. This is of particular
relevance to the beta cell, where correct processing of
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proinsulin to insulin depends on a lysine residue located at the
A-chain/C-peptide cleavage site [3]. Indeed CDKAL1 risk al-
lele carriers display an insulin secretory defect that is concom-
itant with higher levels of proinsulin [4], and beta cell-specific
deletion of Cdkal1 in mice results in glucose intolerance due
to reduced insulin secretion and impaired proinsulin conver-
sion [3]. These observations suggest that diabetes-associated
risk alleles in humans are likely to reduce CDKAL1 activity.
It has been reported that the type 2 diabetes-associated risk
alleles at this locus are associated with lower levels of a non-
coding CDKAL1 splice variant, CDKAL1-v1, which regulates
CDKAL1 activity [5]. Zhou et al showed CDKAL1-v1 con-
tains binding sites for a microRNA, miR-494, that also targets
the full-length CDKAL1 transcript. By competing for
miR-494, CDKAL1-v1 regulates CDKAL1 activity such that
if levels ofCDKAL1-v1 are lower, less miR-494 is sequestered
away from CDKAL1 mRNA and levels of CDKAL1 protein
are reduced [5]. Whilst offering a plausible mechanism under-
lying the type 2 diabetes association, we sought to replicate
their findings in another population and a more disease-
relevant tissue type.
Methods
Participants/nucleic acid extraction The study was carried
out in accordance with the Declaration of Helsinki as revised
in 2008. Clinical and genetic characteristics are presented in
Electronic Supplementary Material (ESM) Table 1. RNAwas
extracted from whole blood of non-diabetic (all donor HbA1c
values <48 mmol/mol) white UK-resident donors using
PAXgene Blood RNATubes (Qiagen, Venlo, the Netherlands)
and PAXgene Blood miRNAKit (Qiagen). DNAwas extracted
fromEDTA tubes using theWizardGenomic DNAPurification
Kit (Promega, Madison, WI, USA). Snap-frozen pancreatic
islets were supplied by ProCell Biotech (Newport Beach, CA,
USA) and the National Institute of Diabetes and Digestive and
Kidney Disease-funded Integrated Islet Distribution Program at
City of Hope (Duarte, CA, USA). RNAwas extracted using the
mirVana miRNA Isolation Kit (Life Technologies, Carlsbad,
CA, USA) and the small amounts of co-eluted genomic DNA
whole genome amplified using the REPLI-gMini Kit (Qiagen).
Genotyping SNPs were genotyped using TaqMan SNP
Genotyping Assays (C_30175809_10, rs9366357;
C_2504058_20, rs7756992) (Life Technologies) and TaqMan
Genotyping Master Mix (Life Technologies).
Quantitative RT-PCR Total RNA was reverse transcribed
using the SuperScript VILO Kit (Life Technologies). For
real-time PCR, TaqManGene ExpressionAssays (ESMTable 2
presents assay IDs/sequences) and TaqMan Fast Advanced
Master Mix (Life Technologies) were used. In islets and in
whole blood fromUK-resident donors,CDKAL1-v1 expression
was normalised using the geometric mean of five (ACTB, B2M,
GUSB, HMBS, RPL11) and two (18S, B2M) housekeeping
genes, respectively. Expression was calculated using the com-
parative Ct method [6] prior to log transformation to create
parametric data suitable for regression analyses. For all regres-
sion analyses involving islet and UK blood samples, expression
data were generated using the CDKAL1-v1 assay without an
oligonucleotide binding to a sequence overlapping rs9366357.
Statistical analysis Regression analyses were performed as-
suming an additive genetic model. In neither UK whole blood
nor islet cohorts were age, sex, BMI or RNA integrity number
values associated with CDKAL1-v1 levels.
Results
The TaqMan assay (Hs01557326) previously used to quantify
CDKAL1-v1 [5] includes an oligonucleotide that binds to a
sequence containing the common SNP, rs9366357, which is
in moderate linkage disequilibrium (LD) with lead type 2
diabetes-associated SNP, rs7756992 (1000 Genomes Pilot 1:
r2=0.3, JPT population; r2=0.28, CEU population).We there-
fore wanted to determine whether the expression quantitative
trait loci (eQTL) finding could be an artefact of allelic dropout
and LD with rs7756992. To address this, we designed another
assay, not including primers/probe overlapping rs9366357, to
measure CDKAL1-v1. In 70 UK blood samples we found that
levels of CDKAL1-v1, quantified using the two TaqMan as-
says, were very highly correlated (r2=0.93). Hence, we do not
believe that the previous results [5] are affected by allelic
dropout.
Having eliminated the possibility that the results from the
Japanese study were due to a technical artefact we sought to
replicate their correlation between rs7756992 genotype and
CDKAL1-v1 levels. Given our sample size of 70, and based
on the per-allele effect size observed in the Japanese study, we
calculated we had >95% power to detect this association (with
a type I error rate of 5%). Indeed, under a simple linear regres-
sion model we also found an effect for rs7756992 on CDKA
L1-v1 levels (β=−0.75, p=0.005) (Fig. 1, Table 1), but no
association with levels of CDKAL1 mRNA (β=0.04,
p=0.61). Furthermore, in contrast to the previous report [5],
there was no correlation between levels of CDKAL1 and
CDKAL1-v1 (r2=0.00, p=0.85).
We remained intrigued by the presence of rs9366357 14 bp
from the unique splice site of CDKAL1-v1. We used
ESEfinder [7] to ascertain whether the alternative alleles of
rs9366357 might affect the binding of any serine/arginine-
rich (SR) proteins which may be important for regulating
CDKAL1-v1 levels. Indeed the T allele was predicted to
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abolish two strong binding sites for the SR protein, SR splic-
ing factor 6. Given this finding, we determined whether there
was any association between rs9366357 and levels of CDKA
L1-v1. In the 70 UK blood samples we found an association
between rs9366357 and CDKAL1-v1 levels in simple linear
regression (β=−1.94, p=3.2×10−23) and in multiple linear
regression, taking into account rs7756992 (β=−1.87,
p=1.3×10−22). The lead type 2 diabetes-associated SNP,
rs7756992, was still associated with CDKAL1-v1 levels when
taking into account rs9366357, although the effect size was
reduced and far smaller than the effect of rs9366357
(β=−0.34, p=0.01) (Fig. 1, Table 1). Subsequently we geno-
typed rs9366357 in the 103 Japanese blood samples described in
the first report detailing theCDKAL1-v1–rs7756992 association
[5]. Again a striking effect of rs9366357 on CDKAL1-v1 levels
was seen (multiple linear regression β=−2.12, p=1.9×10−25),
but in this data set rs7756992 was no longer associated with
CDKAL1-v1 levels when taking into account rs9366357
(β=−0.07, p=0.60) (Fig. 1, Table 1).
We next sought to determine whether CDKAL1-v1 is sim-
ilarly regulated in human pancreatic islets—the primary tissue
of interest with respect to the type 2 diabetes association. In
our cohort of 48 islets from white donors we found, in simple
linear regression analyses, both rs9366357 (β=−1.57,
p=2.4×10−4) and rs7756992 (β=−1.07, p=0.009) to be asso-
ciated withCDKAL1-v1 levels. However, in a multiple regres-
sion model only rs9366357 (β=−1.33, p=0.003), and not
rs7756992 (β=−0.61, p=0.12), was associated with CDKA
L1-v1 expression (Fig. 1, Table 1).
Lastly, we investigated the association between rs9366357
and type 2 diabetes risk in a large case–control study. In data
available from the DIAGRAM consortium, and involving
12,171 cases and 56,862 controls of North European descent,
rs9366357 is only very weakly associated with risk of
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Fig. 1 CDKAL1-v1 levels
stratified by genotype, (a, b) in
whole blood from 70 white
UK-resident donors, (c, d) in
pancreatic islets from 48 white
donors and (e) in whole blood
from 103 Japanese donors. y-axis
values were calculated using the
comparative Ct method with
values relative to the expression
of CDKAL1-v1 in one donor
sample
Table 1 Results of linear regression analyses with CDKAL1-v1 expression as the dependent variable and rs7756992 and rs9366357 as explanatory
variables
Cohort SNP Simple linear regression Multiple linear regression
βa±SE p value βa±SE p value
Whole blood, white UK, n=70 rs7756992 −0.75±0.26 0.005 −0.34±0.13 0.01
rs9366357 −1.94±0.13 3.2×10−23 −1.87±0.13 1.3×10−22
Whole blood, Japan, n=103 rs7756992 −1.04±0.20 1.3×10−6 −0.07±0.14 0.60
rs9366357 −2.16±0.13 9.3×10−31 −2.12±0.15 1.9×10−25
Whole islets, white, n=48 rs7756992 −1.07±0.39 0.009 −0.61±0.39 0.12
rs9366357 −1.57±0.39 2.4×10−4 −1.33±0.42 0.003
a Effect size denotes per minor allele change in log2-transformed expression values
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developing type 2 diabetes (OR 1.05, p=0.003) compared
with the lead SNP, rs7756992 (OR 1.20, p=1.3×10−22). If
differential CDKAL1-v1 expression was heavily involved in
mediating the association between variants at the CDKAL1
locus and type 2 diabetes susceptibility, we would expect
rs9366357, which explains a much larger amount of the var-
iation in levels of CDKAL1-v1 compared with rs7756992, to
be more strongly associated with type 2 diabetes risk. The
small effect of rs9366357 on diabetes risk leads us to conclude
that dysregulated expression of CDKAL1-v1 is unlikely to be
the only genotype-dependent defect driving the association
between genetic variation at the CDKAL1 locus and type 2
diabetes risk.
Discussion
Despite simple regression analyses replicating the association
between lead genome-wide association study (GWAS) SNP
and CDKAL1-v1 levels, our more detailed investigations
mean we can provide strong evidence against a causal role
for this eQTL. Although eQTL studies provide an important
tool for translating GWAS hits, inferring causal mechanisms
should be made with caution, particularly with respect to
cis-eQTLs involving non-coding RNAs. Probably due to low-
er functional constraints, cis-eQTL effect sizes are likely to be
much larger for non-coding RNAs than for protein-coding
transcripts; indeed, this has been reported when comparing
cis-eQTLs involving large intergenic RNAs with cis-eQTLs
involving protein-coding transcripts [8]. This has the poten-
tial, as clearly illustrated by our results, to make non-causal
eQTLs appear causal, even if LD between the two SNPs is
modest (r2<0.7).
Given that highly cell type-specific regulation of gene ex-
pression is possible, our study may be confounded by the
cellular heterogeneity of whole blood and whole islets. Whilst
a study of CDKAL1-v1 expression in sorted pancreatic beta
cells would be ideal, we consider our analysis unlikely to be
strongly confounded: human islets are ∼75% beta cells and
87% of the variance in beta cell gene expression can be ex-
plained by using islet expression as a proxy [9].
Future work should consider the existence of other genes at
the CDKAL1 locus when attempting to decipher causal mech-
anisms. Indeed, whilst physiological characterisation of the
biochemical defect strongly implicates CDKAL1 as the caus-
ative gene, it has been reported that the associated intronic
region contains enhancer elements for the nearby transcription
factor, SOX-4, which is important in pancreas development
and mature beta cell function [10].
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